Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug combo keep CLL at bay for years? a 10-Year watch begins

NCT ID NCT07774390

Knowledge-focused Sponsor: European Research Initiative on CLL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study follows people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who previously received a combination of ibrutinib and venetoclax in the CAPTIVATE trial. Researchers will track their health for up to 10 years to see what treatments they need if the disease returns, how long the initial response lasts, and whether the cancer becomes resistant. Participants may also provide blood samples to check for tiny amounts of remaining cancer cells and genetic changes. The goal is to understand the long-term real-world impact of this treatment combination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ibrutinib plus venetoclax combination therapy
What this could lead to
If successful, this could reveal how long the benefits of ibrutinib plus venetoclax last and what treatments work best when the disease returns, guiding future care for CLL patients.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results depend on real-world data from a specific trial group, which may not apply to all CLL patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 323 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2034

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Only patients enrolled in the CAPTIVATE study will be enrolled in this study.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Individuals who meet all of the inclusion criteria will be eligible to participate in the study. 1. Participant is willing and able to give informed consent for participation in this study. 2. Previously enrolled into the CAPTIVATE study. 3. Being treated in a center that has agreed to participate in this follow-up study. Exclusion Criteria: The only exclusion criterion of this study: 1\. Inability or refusal to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia (CLL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia (CLL) Small lymphocytic lymphoma (SLL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Ospedale San Raffaele

    RECRUITING

    Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.